© The Author 2006. Published by Oxford University Press.
ARTICLE |
Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor
Affiliations of authors: Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Ariake, Koto-ku, Tokyo, Japan (SY, KY, TY); Research Laboratory, Zenyaku Kogyo Co., Ltd., Ohizumi-machi, Nerima-ku, Tokyo, Japan (SY, IK, HY, TM); Laboratory of Biological Chemistry, Department of Applied Biological Chemistry, Faculty of Agricultural and Life Science, Graduate School of Agricultural and Life Science, University of Tokyo, Yayoi, Bunkyo-ku, Tokyo, Japan (YF); The School of Pharmaceutical Sciences, Kitasato University, Shirokane, Minato-ku, Tokyo, Japan (HG, SH)
Correspondence to: Takao Yamori, PhD, Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan (e-mail: yamori{at}jfcr.or.jp).
Background: We previously synthesized a novel s-triazine derivative, ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], that strongly inhibited the growth of tumor cells. We identified its molecular target, investigated its effects on cellular signaling pathways, and examined its antitumor efficacy and toxicity in vivo. Methods: We used COMPARE analysis of chemosensitivity measurements from 39 human cancer cell lines and identified phosphatidylinositol 3-kinase (PI3K) as a molecular target for ZSTK474. PI3K was immunoprecipitated from A549 cell lysates, and its activity was measured by assessing the incorporation of 32P into phosphatidylinositol. We used the crystal structure of the PI3K–LY294002 complex to model the binding of ZSTK474 to PI3K (where LY294002 is a known PI3K inhibitor). PI3K downstream activity was analyzed by immunoblotting. Antitumor activity of ZSTK474 was examined against A549, PC-3, and WiDr xenografts in nude mice. Phosphorylation of Akt, a serine/threonine protein kinase and a major signaling component downstream of PI3K, was assessed in vivo by immunohistochemistry. Results: PI3K was identified as a molecular target for ZSTK474 by COMPARE analysis. We confirmed that ZSTK474 directly inhibited PI3K activity more efficiently than the PI3K inhibitor LY294002. At concentrations of 1 µM, ZSTK474 and LY2194002 reduced PI3K activity to 4.7% (95% confidence interval [CI] = 3.2% to 6.1%) and 44.6% (95% CI = 38.9% to 50.3%), respectively, of the untreated control level. Molecular modeling of the PI3K–ZSTK474 complex indicated that ZSTK474 could bind to the ATP-binding pocket of PI3K. ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3
, and mediated a decrease in cyclin D1 levels. ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in critical organs. Akt phosphorylation was reduced in xenograft tumors after oral administration of ZSTK474. Conclusion: ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs. ZSTK474 merits further investigation as an anticancer drug.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Link, J. Oyarzabal, B. G. Serelde, M. I. Albarran, O. Rabal, A. Cebria, P. Alfonso, J. Fominaya, O. Renner, S. Peregrina, et al. Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases J. Biol. Chem., October 9, 2009; 284(41): 28392 - 28400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Oh, J. H. Youn, Y. Ji, S. E. Lee, K. J. Lim, J. E. Choi, and J.-S. Shin HMGB1 Is Phosphorylated by Classical Protein Kinase C and Is Secreted by a Calcium-Dependent Mechanism J. Immunol., May 1, 2009; 182(9): 5800 - 5809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Aziz, M. Davies, E. Pick, C. Zito, L. Jilaveanu, R. L. Camp, D. L. Rimm, Y. Kluger, and H. M. Kluger Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma Clin. Cancer Res., May 1, 2009; 15(9): 3029 - 3036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marone, D. Erhart, A. C. Mertz, T. Bohnacker, C. Schnell, V. Cmiljanovic, F. Stauffer, C. Garcia-Echeverria, B. Giese, S.-M. Maira, et al. Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors Mol. Cancer Res., April 1, 2009; 7(4): 601 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Levy, J. A. Kahana, and R. Kumar AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines Blood, February 19, 2009; 113(8): 1723 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Prevo, E. Deutsch, O. Sampson, J. Diplexcito, K. Cengel, J. Harper, P. O'Neill, W. G. McKenna, S. Patel, and E. J. Bernhard Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity Cancer Res., July 15, 2008; 68(14): 5915 - 5923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther., July 1, 2008; 7(7): 1851 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Hers Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3K{alpha} pathway Blood, December 15, 2007; 110(13): 4243 - 4252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nakatsu, T. Nakamura, K. Yamazaki, S. Sadahiro, H. Makuuchi, J. Kanno, and T. Yamori Evaluation of Action Mechanisms of Toxic Chemicals Using JFCR39, a Panel of Human Cancer Cell Lines Mol. Pharmacol., November 1, 2007; 72(5): 1171 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ma, J. Wang, Y. Gao, T.-W. Gao, G. Chen, K. A. Bower, M. Odetallah, M. Ding, Z. Ke, and J. Luo The Role of Glycogen Synthase Kinase 3{beta} in the Transformation of Epidermal Cells Cancer Res., August 15, 2007; 67(16): 7756 - 7764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. I. Raynaud, S. Eccles, P. A. Clarke, A. Hayes, B. Nutley, S. Alix, A. Henley, F. Di-Stefano, Z. Ahmad, S. Guillard, et al. Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases Cancer Res., June 15, 2007; 67(12): 5840 - 5850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Naslavsky, J. Rahajeng, S. Chenavas, P. L. Sorgen, and S. Caplan EHD1 and Eps15 Interact with Phosphatidylinositols via Their Eps15 Homology Domains J. Biol. Chem., June 1, 2007; 282(22): 16612 - 16622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, M. Tseng, S. A. Perdreau, F. Rossi, C. Antonescu, P. Besmer, J. A. Fletcher, S. Duensing, and A. Duensing Histone H2AX Is a Mediator of Gastrointestinal Stromal Tumor Cell Apoptosis following Treatment with Imatinib Mesylate Cancer Res., March 15, 2007; 67(6): 2685 - 2692. [Abstract] [Full Text] [PDF]
|
|